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Summary
Essential thrombocythemia is an indolent clonal hematological neoplasm. The JAK2 V617F 
mutation can be identified in the half of the patients. However, the detection of new mutations 
(calreticulin and MPL) and their potential consequences on biological behavior, diagnosis and 
further treatment approaches should be defined in future investigations and clinical studies. The 
assessment of the risk for thrombosis continues to be essential for therapeutic approach.
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INTRODUCTION
Essential thrombocythemia (ET), together with polycythemia vera (PV) and pri-
mary myelofibrosis (PMF), is a clonal Ph-negative myeloproliferative neoplasm (Ph-
MPN), characterized by thrombocytosis, bone marrow megakaryocytic hyperplasia 
and a tendency to develop vascular complications [1]. 
The etiology of the disease is unknown, incidence is 0.6-2.5/100,000 per year and 
the median age at onset is 65-70 years. ET it is slightly more frequent in males than 
in females [2].
Pathogenesis
The milestone for the understanding of MPN pathogenesis is identification of 
acquired Janus kinase2 (JAK2) V617F mutation. The detection of this molecular le-
sion, from either peripheral blood cells or bone marrow cells, in at least 50-60% of 
ET patients is important for diagnosis [3]. JAK is a protein involved in intracellular 
transduction of signals originating from thrombopoetin receptor, predominantly 
through JAK-STAT pathway [4]. Several studies suggest that JAK2 V617F positive 
cases share some features with PV such as higher hemoglobin values, higher num-
Rad 524. Medical Sciences, 42 (2015) : 127-134
T. Valković: Essential thrombocythemia
128
ber of neutrophils, more thrombotic complications and more frequent incidence of 
fibrotic marrow transformation [5,6]. It seems that JAK2 allele burden is higher in 
patients with PV, PMF, or post-PV MF than in those with ET and homozygosity for 
JAK2 mutation is pretty rare in ET, suggesting that mutated allele burden is an im-
portant factor which determines MPN phenotype [7]. 
Recently, two other molecular lesions have been identified in ET and PMF 
patients contributing to our understanding of disease pathogenesis, but also to 
the diagnostic process. The calreticulin (CALR) gene mutation (19p13.2) can be 
detected in approximately 15-24 % of ET patients, who are usually JAK-2 V617F 
negative [8]. CALR is a multi-functional Ca2+ binding chaperone localized 
mostly in the endoplasmic reticulum, but can also be found in nuclei implicating 
possible role in transcription. In ET, mutant CALR is associated with younger 
age, male gender, lower leukocyte and hemoglobin values, higher number of 
platelets and decreased rick for thrombotic events [8,9]. Additionally, MPL (mye-
loproliferative leukemia gene) mutations occur in less than 5% of patients with 
ET [10]. These molecular lesions cluster in exon 10 and the most frequent among 
them is MPLW515L/K mutation [11]. In some investigations, MPL mutations have 
been associated with older age, female sex, higher number of platelets and lower 
hemoglobin value [12]. Furthermore, JAK2 and MPL mutations can be detected 
in other myeloid neoplasms, while other mutations such as TET 2, ASXL1, IDH 
are sometimes found in ET [13]. Finally, approximately 20% of patients with ET 
show a triple negative mutation status.
Clinical presentation
The patients are often asymptomatic and the disease is revealed after routine 
blood tests (complete blood cell count). Arterial or/and venous thrombosis (myo-
cardial infarction, stroke, pulmonary embolism, deep vein thrombosis) occurs in 
approximately 20 % of patients. Hemorrhagic complications, such as easy bruising, 
mucosal and gastrointestinal bleeding, as well as prolonged bleeding after surgery, 
occur in 25 % of patients and sometimes can be life threatening. Common presenta-
tion may include microvascular symptoms due to microvascular occlusion such as 
paresthesia, headache, dizziness, syncope, visual disturbances, atypical chest pain, 
erythromelalgia (burning sensation, pain and erythema in hands or feet) or livedo 
reticularis.
Recurrent abortions and fetal growth retardation can also be a part of clinical 
presentation in fertile women. The constitutional symptoms are not common sugge-
sting possible transformation of disease. Fatigue is not uncommon.
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Diagnosis 
Complete blood count shows persistent thrombocytosis (platelet count > 450x109/l, 
but may be as high as 4000-5000 x109/L), hemoglobin level and white blood count are 
usually normal, but normocytic anemia or leukocytosis can be present. Blood film 
shows numerous platelets, variable in shapes and sizes. Neutrophilia and basophila 
are not uncommon. Bone marrow aspirate is not reliable for diagnosis, however it can 
show an increased number of atypical megakaryocytes and cluster formation. The 
bone marrow biopsy is extremely important, showing megakaryocytic hyperplasia 
with clustering and nuclear pleomorphism. Reticulin in bone marrow is normal or 
increased. The analysis of JAK2 V617F mutational status and allele burden is manda-
tory. Cytogenetic and molecular abnormalities characteristic for other myeloprolife-
rative diseases, such as Ph+ chronic myeloid leukemia (Ph+ CML) or myelodysplastic 
syndrome (MDS), must be tested, especially the bcr/abl fusion gene. Cytogenetic ab-
normalities occur in 5% of the cases (mainly affecting chromosomes 20, 1, 8, 9).
In the absence of clonal markers the reactive thrombocytosis, caused by many 
factors (eg. infections, malignant tumors, post surgical, post splenectomy, severe 
burns, chronic bleeding, hemolysis, rheumatologic disorders, inflammatory bowel 
disease, Ph+ CML, MDS, etc), must be excluded.
The World Health Organization (2008) criteria for ET [14] are shown in Table 1.
Table 1. World Health Organization Diagnostic Criteria for Essential Thrombocythemia, 2008.
Diagnosis requires all criteria listed below:
1. sustained platelet count ≥ 450x109/L
2. Bone marrow biopsy showing megakaryocyte proliferation with increased numbers of 
enlarged, mature megakaryocytes, no or little granulocyte or erythroid proliferation.
3. Not meeting WHO criteria for PV, primary myelofibrosis, BCR-ABL positive CML, MDS, 
or other myeloid neoplasm.
4. Demonstration of JAK2 V617F or other clonal marker, or in the absence of JAK2 V617F 
mutation, no evidence of reactive thrombocytosis.
Risk stratification 
Vascular events are the most frequent, sometimes life threatening complications 
because of which the risk stratification for thrombosis is essential to decide whether 
cytoreductive therapy should be initiated or not. For each patient the individual 
thrombotic risk must be evaluated because it defines the therapeutic approach. 
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The standard high-risk factors are age over 60 years and prior history of throm-
bosis [15]. Furthermore, JAK2 V617F mutational status and allele burden [16], as well 
as standard cardiovascular risk factors [15] can additionally increase the thrombotic 
risk. Leukocytosis and anemia have also been reported to have a negative impact 
on survival but only in some studies [17]. All these additional factors should also be 
considered before making a decision to initiate therapy. 
On the other hand, “extreme” thrombocytosis (defined as platelets number 
>1000x109/L for some and > 1500x109/L for others) is considered to be a risk factor 
for bleeding caused by different abnormalities of platelet function or acquired von 
Willebrand syndrome [18]. Because of this, in this group of patents ristocetin cofac-
tor activity should be tested. Paradoxically, “extreme” platelet number was found to 
show a protective effect against thrombosis [19].
Treatment 
The main goals of the treatment of patients with ET are maintaining the platelet 
number in normal range through the use of cytoreductive drugs, as well as modu-
lating the platelet function through the use of aspirin, which together reduce the 
incidence of vascular symptoms and complications.
Currently, there are a few cytoreductive drugs used in every-day practice. Hy-
droxyurea is a traditional antineoplastic drug used as first line therapy in ET since 
Cortelazzo et al published the results on its efficiency in reducing the platelet num-
ber and vascular complications [20]. There is some concern regarding a possible 
increased risk of leukemic transformation and teratogenic effect. However, the leu-
kemogenic potential of this drug is not definitely proven. Thus, in many centers hy-
droxyurea is restricted for patients older than 60 years. Interferon-alpha, standard 
and pegylated form, was shown to reduce thrombocytosis, and can even induce 
molecular response [21]. In some studies pegylated interferon also reduced the pro-
gression of fibrosis [22]. It is a drug of choice for young patients or pregnant fema-
les because, according to our knowledge, it is not teratogenic or oncogenic. Finally, 
anagrelid is a selective inhibitor of megakaryocyte differentiation which reduces 
the platelet number. This drug has been approved for treatment of patients with 
ET based on a single arm study [23]. Harrison et al published the results of a ran-
domized comparison of hydroxyurea and anagrelide in ET patients. In this study 
hydroxyurea showed to be superior to anagrelide in terms of bleeding incidence, 
arterial thrombosis and myelofibrotic transformation, but inferior in terms of ve-
nous thrombosis [24]. Consequently, anagrelide became the second line therapy for 
patients in whom hydroxyurea or interferon are inadequate or not tolerated.
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The low-dose aspirin is widely used in ET patients because of its potential to 
reduce thrombotic events in those who don’t have contraindications to this drug. 
In patients with an “extreme” platelet number: ≥1500x109/L, an acquired von Wille-
brand deficit may be present. In these cases cytoreductive therapy should be started 
before aspirin initiation. The risk-adopted therapy used in our institution is descri-
bed in Table 2.
Patients should be advised to stop smoking, control body weight, hypertension, 
hyperlipidemia or diabetes. The regular exercise is recommended.
Several experimental drugs (e.g. JAK2 inhibitors, telomerase inhibitors) are cu-
rrently being evaluated in clinical studies.
Table 2. Risk Stratification and Risk-Adopted Therapy
Risk category Risk factors Therapy
Low Age < 60 years and no thrombosis history; platelets < 1000 x 109/L Low-dose aspirin*
High Age > 60 years and/or thrombosis history; platelets ≥1000 x 109/L
Cytoreductive drugs: 
- hydroxyurea (age ≥ 60 years)
-  interferon a (age <60 years, in 
pregnancy)
-  anagrelide (second line therapy) 
Low-dose aspirin*
* if there are no: contraindications for aspirin, “extreme” thrombocytosis or acquired von Willebrand deficit
Prognosis
ET is an indolent clonal hematological disorder with good prognosis and in whi-
ch life expectancy is near normal. However, recent results of Tefferi et al. showed 
that, despite the very long survival of patients with ET, their life expectancy rema-
ined inferior to the age- and sex-matched US population (the median survival was 
19,8 years for all patients and 32,7 years for patients younger than age 60) [25].
Risk factors for a shortened survival in both PV and ET include advanced age, 
leukocytosis, and history of thrombosis [15].
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Esencijalna trombocitemija je indolentna hematološka novotvorina. Mutacija JAK2 V617F 
gena je prisutna u polovice bolesnika. Ipak, otkriće mutacija novih gena (kalretikulin i MPL) te 
njihova potencijalna uloga u biološkom ponašanju bolesti, njenoj dijagnostici, kao i budućem 
liječenju tek se mora definirati u nadolazećim istraživanjima i kliničkim ispitivanjima. Procjena 
rizika za trombozu i dalje je osnova za kreiranje terapijskog pristupa.
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